FNY Investment Advisers’s Sagimet Biosciences SGMT Stock Holding History

FNY Investment Advisers’s Portfolio SGMT Stock Details SGMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$844K	Sell	109,250 -40,511	-27%	-$275K	0.3%	100
2026 Q1	$782K	Buy	149,761 +6,880	+5%	+$38.3K	0.34%	74
2025 Q4	$845K	Buy	142,881 +32,231	+29%	+$232K	0.24%	97
2025 Q3	$759K	Buy	110,650 +23,906	+28%	+$194K	0.24%	127
2025 Q2	$660K	Sell	86,744 -94,256	-52%	-$398K	0.28%	102
2025 Q1	$590K	Buy	181,000 +50,750	+39%	+$213K	0.36%	69
2024 Q4	$586K	Sell	130,250 -17,669	-12%	-$89.5K	0.3%	77
2024 Q3	$409K	Sell	147,919 -11,023	-7%	-$34K	0.2%	113
2024 Q2	$543K	Buy	158,942 +125,442	+374%	+$575K	0.36%	51
2024 Q1	$181	Buy	+33,500	New	+$241K	0.11%	133

Other funds holding SGMT

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $31B AUM 28.39% 1-Year Est. Return

MMA

Miracle Mile Advisors Los Angeles, California $8.53B AUM 21.43% 1-Year Est. Return

APG

Abacus Planning Group Columbia, South Carolina $809M AUM 21.71% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

NFG

Nations Financial Group Cedar Rapids, Iowa $2.09B AUM 34.27% 1-Year Est. Return

PFG Investments Woodbury, New York $2.58B AUM 36.93% 1-Year Est. Return

CUAMC

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

FNY Investment Advisers's SGMT Position: Q2 2026 in Review

FNY Investment Advisers reduced its Sagimet Biosciences (SGMT) stake by 27% in Q2 2026, selling an estimated $275K and leaving 109,250 shares worth $844K. The position accounts for 0.3% of the portfolio, ranked #100.

FNY Investment Advisers first reported a position in SGMT in Q1 2024 and has held it in 10 quarters since. The position peaked at $845K in Q4 2025. 14 funds tracked by Wall St. Rank hold SGMT as of Q2 2026.

FNY Investment Advisers held 109,250 shares of Sagimet Biosciences worth $844K as of Q2 2026.
FNY Investment Advisers sold 40,511 Sagimet Biosciences shares in Q2 2026, an estimated $275K.
Sagimet Biosciences made up 0.3% of FNY Investment Advisers's portfolio in Q2 2026, its #100 holding.
FNY Investment Advisers first reported a position in Sagimet Biosciences in Q1 2024 and has held it in 10 quarters since.
FNY Investment Advisers's Sagimet Biosciences position peaked at $845K in Q4 2025.
14 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2026.

Based on FNY Investment Advisers's 13F filing for Q2 2026, filed 8 Jul 2026.